Figures

Numbers that matter

Number of employees

Currently showing figure for the year 2025

Net Sales, EUR million

Currently showing figure for the year 2025

Human Pharma Net Sales, EUR million

Currently showing figure for the year 2025

Animal Health Net Sales, EUR million

Currently showing figure for the year 2025

R&D expenses, EUR million

Currently showing figure for the year 2025

R&D expenses, Human Pharma, EUR million

Currently showing figure for the year 2025

R&D expenses, % of Human Pharma Net Sales

Currently showing figure for the year 2025

Our purpose is to transform the lives of patients and animals for generations. Boehringer Ingelheim has been developing pharmaceutical breakthroughs that increase survival rates and improve quality of life for more than 140 years. Independent and family-owned, we pursue a strategy to secure our independence through the research, development, production and marketing of innovation-based solutions.

[**Find out more in our Highlights** 5min](/content/annualreport/2025/files/Boehringer-Ingelheim-Annual-Report-Highlights-2025.pdf "Find out more in our Highlights"/index.html)

• Net Sales by Business
• Net Sales by Region
• R&D Expenses

Net Sales by Business

Select Year:

• 2023
• 2024
• 2025

Visualization:

• Bar Chart

• Table

• 2023

• 2024

• 2025

• Top Products Human Pharma
• Top Products Animal Health

Net Sales 2025 in EUR million

FAQs

How did our product portfolio change last year?

Within our Human Pharma Business, two products emerged as big growth drivers: Firstly, JARDIANCE®, for Type 2 diabetes, chronic kidney disease and heart failure, reached sales of EUR 8.8 billion. This represents a currency-adjusted growth of +8.7%. The second key driver was OFEV®, our antifibrotic therapy approved in three indications, which reached sales of EUR 3.8 billion and grew currency-adjusted by +5.4%.

Key drivers of our Animal Health business were in our Livestock and Pet business with three products to highlight in particular: NEXGARD®, our largest Animal Health product, had sales of EUR 1.4 billion. The parasiticide for dogs (helping to kill fleas, ticks and mites) grew currency-adjusted by +8.5%. FRONTLINE®, another product of our parasiticides business, reached sales of EUR 370 million. BULTAVO® 3, which supported throughout the outbreak of the bluetongue disease, more than doubled sales in 2025.

What are our pivotal areas of development?

Our key therapeutic areas in Human Pharma include cardiovascular, renal and metabolic health, cancer, eye health, inflammatory diseases, obesity, and liver health.

What are our primary markets?

Boehringer Ingelheim operates in several key markets both geographically and therapeutically. Geographically, North America is one of our largest markets, particularly the United States, that makes a significant contribution to our revenue. Europe is also a vital region, with significant operations in Germany, where our company is headquartered. In Asia, countries like China and Japan are important due to their large populations and growing healthcare needs. Latin America also plays a crucial role, with notable markets in Brazil and Mexico. We also have a presence in the Middle East, Africa, and Australia.

Therapeutically, Boehringer Ingelheim focuses on several areas within human pharmaceuticals. We have a strong presence in cardiovascular, renal, and metabolic diseases, offering treatments for conditions like diabetes, chronic kidney disease, and heart failure, with products such as JARDIANCE®. In oncology, we are building a broad portfolio, including HERNEXEOS®, our first in-class targeted therapy for HER2-mutant NSCLC. We are also developing treatments for various cancers, including rare types like dedifferentiated liposarcoma. Our respiratory disease portfolio includes products like JASCAYD® and OFEV® for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. We also focus on immunology, mental health, and retinal health, addressing diseases affecting the immune system and the retina.

In addition to human pharmaceuticals, Boehringer Ingelheim is a global leader in the animal health industry. We work on innovative solutions for the prediction, prevention, and treatment of diseases in animals, reflecting our commitment to improving health for both humans and animals through innovative therapies and solutions.

What was our R&D investment in 2025?

In 2025, we invested EUR 6.4 billion to drive our innovation agenda, representing 22.9% of our company-wide net sales. The Human Pharma business recorded an even higher R&D ratio of 27.4%, keeping us well above the industry average. In Animal Health, investments reached EUR 0.5 billion, corresponding to 10.7% of net sales.